Your insurance denied Ozempic, Wegovy, or Mounjaro? You may have appeal options.
GLP-1 medications are among the most denied prescriptions in America — for weight management especially, denials are routine. Many turn on prior-authorization rules, step therapy, plan exclusions, and clinical documentation.
Upload your denial letter. Lysco identifies the exact reason, maps the step-therapy and exception arguments that fit it, and drafts an appeal with clinical citations. Your first read is free.
The numbers
PA
Many GLP-1 denials turn on prior-auth, step-therapy, or plan-exclusion rules
Plan criteria
5%
Of ACA marketplace in-network denial reasons were medical necessity
KFF, 2024 data
<1%
Of denied in-network claims were appealed
KFF, 2024 data
Jul 2026
Medicare begins GLP-1 bridge coverage
CMS, 2026
These are aggregate U.S. denial-appeal statistics across all categories — they describe a population, not a prediction for your case. GLP-1 outcomes specifically depend on your plan’s step-therapy rules, BMI/comorbidity criteria, and the clinical documentation your prescriber provides.
Drugs we handle
Lysco handles denials for every major GLP-1
Ozempic
Type 2 diabetes
Wegovy
Weight management
Mounjaro
Type 2 diabetes
Zepbound
Weight management
Rybelsus
Type 2 diabetes (oral)
Saxenda
Weight management
Trulicity
Type 2 diabetes
Victoza
Type 2 diabetes
Other GLP-1s
Any brand or generic
Denial playbook
Why insurers deny GLP-1s — and what works in appeal
Step therapy not completed
Insurers often require you to “fail” cheaper drugs (metformin, phentermine) first. If you’ve documented intolerance, contraindication, or prior failure, that waives the requirement. Upload those records and Lysco builds the argument from them.
BMI or comorbidity threshold not met
Most plans require BMI ≥30, or ≥27 with a weight-related condition (hypertension, sleep apnea, prediabetes, dyslipidemia). Upload your clinical notes and Lysco matches them against the criteria your denial letter cites.
Weight-loss use not covered
Many plans exclude weight-management indications but cover Type 2 diabetes. If you have related conditions, we cite ADA and endocrinology guidelines for broader medical necessity.
Prior authorization required
Many GLP-1 denials are PA failures, step-therapy issues, or plan-exclusion questions rather than a pure medical rejection. We build the PA with the documentation the insurer needs.
Plan formulary exclusion
If the specific drug isn’t on formulary but a similar GLP-1 is, we request a formulary exception with clinical justification for why your prescriber chose this one.
Quantity or dose limits
If your prescriber escalated your dose per the approved titration schedule, the denial is often procedurally wrong. We cite the FDA-approved titration.
What changed
Why 2026 is different
Medicare is opening up. Starting July 2026, Medicare will begin offering a GLP-1 bridge — the first time traditional Medicare beneficiaries get coverage for weight-management indications.
State Medicaid is contracting. Pennsylvania, California, New Hampshire, and South Carolina have cut or limited GLP-1 coverage in 2026. If you’re on Medicaid and lost coverage, an appeal — or a shift to a covered indication — may still work.
Commercial plans are tightening. Expect stricter prior-auth criteria, more step-therapy requirements, and more aggressive denials. The stronger your documentation, the higher your odds. Lysco builds that documentation into every appeal letter.
The process
How Lysco appeals a GLP-1 denial
Upload the denial or PA rejection
Photo, PDF, or paste the text. We read it in seconds and extract the specific reason.
We identify the fix
Step therapy? BMI threshold? Formulary exclusion? We match the denial to the right appeal argument.
We draft the appeal with clinical citations
ADA guidelines, endocrinology society statements, FDA-approved titration schedules, and your plan’s own policy language.
You review, sign, and send
Or give it to your prescriber to co-sign. We include the exact submission address and deadline.
Start your GLP-1 appeal — free
Your first read is free. 30 seconds to upload. No credit card needed.
Appeal my GLP-1 denialHIPAA-aligned · Bank-level encryption · Delete anytime
Lysco is an informational tool — not a law firm, medical provider, or licensed patient advocate. We don’t prescribe or recommend medications. GLP-1 prescribing is a decision for you and your doctor. Appeal outcomes vary by plan, diagnosis, documentation, and circumstances. This page is not medical or legal advice. Ozempic, Wegovy, Mounjaro, and Zepbound are trademarks of their respective manufacturers.